Literature DB >> 22984195

Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.

Dagmar-Christiane Fischer1, Anne Mischek, Sabrina Wolf, Anja Rahn, Birgit Salweski, Guenther Kundt, Dieter Haffner.   

Abstract

BACKGROUND: Paediatric reference values for novel markers of phosphate homeostasis, bone formation and resorption and their putative relationship to growth are lacking.
METHODS: A total of 424 healthy children, adolescents and young adults (221 males) aged 0.1-21 y, were enrolled in this cross-sectional study. Height, weight and height velocity were assessed. Plasma/serum samples for determination of C-terminal fragment of fibroblast growth factor-23 (cFGF-23), sclerostin, bone alkaline phosphatase (BAP) and tartrate-resistant acid phosphatase 5b (TRAP5b) were available from 222, 264, 352 and 338 individuals, respectively. Calculation of cross-sectional centiles and z-scores was based on median (M), standard coefficient of variation (S) and the Box-Cox power (L) of transformation (LMS method) per age cohort. Correlations between variables as well as with growth were assessed.
RESULTS: cFGF-23, BAP and TRAP5b were significantly correlated with age (each P < 0.01), with highest values during infancy and adolescence. Serum levels of BAP and TRAP5b were significantly higher in adolescent boys compared with girls (each P < 0.01). In contrast, sclerostin levels were independent of age and gender. BAP and TRAP5b were strongly correlated and both were significantly associated with cFGF-23 and sclerostin as well (each P < 0.01). cFGF-23 was positively correlated with serum phosphate and renal phosphate threshold concentration (each P < 0.01). Height, weight, body mass index and height velocity were weakly correlated with BAP and TRAP5b (each P < 0.05).
CONCLUSIONS: This study provides age- and gender-related centile charts and z-scores for cFGF-23, BAP, TRAP5b and sclerostin and highlights the link between phosphate homeostasis and markers of bone metabolism during growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22984195     DOI: 10.1258/acb.2012.011274

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  38 in total

Review 1.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

2.  Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children.

Authors:  Svenja Kristin Kunert; Hans Hartmann; Dieter Haffner; Maren Leifheit-Nestler
Journal:  J Bone Miner Metab       Date:  2016-03-26       Impact factor: 2.626

3.  Disordered FGF23 and mineral metabolism in children with CKD.

Authors:  Anthony A Portale; Myles Wolf; Harald Jüppner; Shari Messinger; Juhi Kumar; Katherine Wesseling-Perry; George J Schwartz; Susan L Furth; Bradley A Warady; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 8.237

4.  Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure.

Authors:  Tamara Isakova; Jessica Houston; Laura Santacruz; Eva Schiavenato; Gabriel Somarriba; William G Harmon; Steven E Lipshultz; Tracie L Miller; Paolo G Rusconi
Journal:  Pediatr Nephrol       Date:  2013-06-06       Impact factor: 3.714

5.  Severe hypercalcemia following denosumab treatment in a juvenile patient.

Authors:  Nokitaka Setsu; Eisuke Kobayashi; Naofumi Asano; Naoko Yasui; Hiroshi Kawamoto; Akira Kawai; Keisuke Horiuchi
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

Review 6.  From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.

Authors:  Vincent M Brandenburg; Patrick D'Haese; Annika Deck; Djalila Mekahli; Björn Meijers; Ellen Neven; Pieter Evenepoel
Journal:  Pediatr Nephrol       Date:  2015-03-04       Impact factor: 3.714

7.  FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls.

Authors:  Deborah M Mitchell; Harald Jüppner; Sherri-Ann M Burnett-Bowie
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

Review 8.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

9.  Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.

Authors:  Erik A Imel; Amie K Gray; Leah R Padgett; Michael J Econs
Journal:  Bone       Date:  2013-12-08       Impact factor: 4.398

Review 10.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.